Teresa Company Messa: ”Evolution, Commitment, and Innovation” Perfectly Sum up Last Week’s Event
Teresa Company Messa, Market Development Manager at Werfen, shared on LinkedIn:
”Evolution, commitment, and innovation
Three big words, but ones that perfectly sum up last week’s event: the launch of the 70 Series, a new generation of analyzers that mark another step forward in our mission to advance hemostasis diagnostics.
And there could be no better setting than La Pedrera.
Just as Gaudà challenged the limits of his time to transform architecture, we continue to push the limits of technology to transform diagnostics.
And for those of you who are not part of this world, you may ask yourselves: what does this have to do with me?
Everything.
Because behind every sample there is a person, and that person could be you, it could be me.
At Werfen, we work every day with a firm commitment to ensuring the highest quality, accuracy, and service for laboratory professionals and, ultimately, for patients.”
Stay updated with Hemostasis Today.
-
Feb 23, 2026, 13:02Deepak Yadav: What 2025 Evidence Tells Us About Stroke Care
-
Feb 23, 2026, 12:55Radoslaw Kaczmarek: Will AAV Gene Therapy for Hemophilia Trigger Tumorigenesis?
-
Feb 23, 2026, 12:46Heghine Khachatryan: More Granular Risk Stratification Framework for PE from The New 2026 AHA/ACC Guideline
-
Feb 23, 2026, 12:37Reza Shojaei: EU’s Critical Medicines Act and Plasma Resilience
-
Feb 23, 2026, 12:32Anirban Sen Gupta: Emily Mihalko Highlights PlateChek at MTEC
-
Feb 23, 2026, 12:25Ryan Williams: Excellent Highlights on The Heterogeneity of PRP Preparation
-
Feb 23, 2026, 12:10Peter Libby: hsCRP May Select Patients Who Can Benefit From Statins or Anti-inflammatory Therapy
-
Feb 23, 2026, 12:02Marios Georgakis: An Unprecedented for An Antithrombotic Therapy from OCEANIC-STROKE Trial
-
Feb 23, 2026, 11:37Charles Okyere Boadu: Blood Donation Helps Lower Your Risk of Stroke and Organ Damage